Achilles Therapeutics plc announced a research collaboration with Arcturus Therapeutics Holdings Inc., to evaluate best-in-class, self-amplifying mRNA (sa-mRNA) personalized cancer vaccines (PCVs) targeting clonal neoantigens. The research collaboration will combine Achilles? best-in-class AI-driven, tumor-targeting technology with Arcturus?

sa-mRNA platform. The collaboration has the potential to generate IND-enabling data which demonstrate the ability of PELEUS to select multiple, highly immunogenic clonal neoantigens that can be expressed with the Arcturus STARR® platform to generate potent and durable T cell responses. Any subsequent clinical development will be jointly agreed by the parties.